/
Such factors include, among others, the following: general economic and business conditions, including, without limitation, a potential economic downturn, supply chain challenges and constraints, including the availability and cost of materials, the effects of inflation, and increased interest rates; compliance with and changes in laws and regulatory requirements; the failure of any enterprise-…
$43.66
+$0.46 (+1.06%)
Live · 05:23 PM
Operating margin is thin at 7.46%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 5.2%, steady but not accelerating. Margins contracted 7.9pp, which offsets some of the top-line progress.
At 29x earnings, the current multiple leaves limited room for execution misses or growth deceleration. ROIC dropped from 9.08% to 4.10%, capital efficiency is deteriorating.
28.9x earnings, 9.0x FCF. Not cheap, the quality is already reflected in the price. Upside from here requires either margin expansion or growth re-acceleration, not just continuation.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$1.37B
▲ +5.2% YoY
Net Income (TTM)
$47M
▼ -64.5% YoY
Op. Margin
7.46%
▼ -7.9pp YoY
ROIC
4.10%
▼ -5.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$151M
▼ -2.0% YoY
Op. Cash Flow (TTM)
$171M
▲ +2.2% YoY
Net Debt
$848M
Cash & Equiv.
$41M
5Y CAGR: +9.8%
5Y CAGR: +24.0%
Continue Research
At a P/E of 28.9 and a price-to-free-cash-flow of 9.0, CONMED (CNMD) trades below a two-stage DCF intrinsic value of about $103.17 per share, so at $43.66 the stock looks undervalued (136.3% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, CONMED scores 60/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 1.8%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $103.17 per share for CNMD, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $77.38. At today's $43.66, that puts the stock about 136.3% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
CONMED scores 60 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a 7.5% operating margin and a 4.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, CONMED pays a regular dividend of about $0.79 per share per year (typically in quarterly installments), a yield of roughly 1.8% at the current price. That is a payout ratio of about 52.6% of earnings, so the dividend is well covered. CONMED has grown the dividend at roughly 1.6% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For CNMD's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. CNMD currently trades below its estimated intrinsic value and scores 60/100 on quality (solid). It also yields about 1.8%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.